MO26-5 HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer von Sawada, Kentaro, Kawamoto, Yasuyuki, Yuki, Satoshi, Nakamura, Michio, Muto, Osamu, Sogabe, Susumu, Shindo, Ysohiaki, Ishiguro, Atsushi, Sato, Atsushi, Tsuji, Yasushi, Dazai, Masayoshi, Okuda, Hiroyuki, Sasaki, Takahide, Harada, Kazuaki, Nakano, Shintaro, Nakatsumi, Hiroshi, Sekiguchi, Mari, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

Volltext